In a recent study by Lonial et al¹ in the Journal of Clinical Oncology, it was concluded that among patients with high-risk smoldering multiple myeloma (SMM), early intervention with lenalidomide (len) could delay progression to symptomatic multiple myeloma (MM). It was proposed by the authors that these data, together with the results of the randomized Spanish trial,² represent a new standard of care for patients with high-risk SMM.

中文翻译：

---

阴燃性骨髓瘤的治疗：研究设计存在的问题以及生物学和临床意义

Lonial等[ ^1]在《临床肿瘤学杂志》上的最新研究中得出的结论是，在高风险的闷烧多发性骨髓瘤（SMM）患者中，来那度胺（len）的早期干预可延缓症状性多发性骨髓瘤（MM）的进展。 。作者提出，这些数据以及西班牙随机试验的结果²代表了高危SMM患者的新护理标准。